These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28091987)

  • 21. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
    Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis.
    Liu Z; Che P; Mercado JJ; Hackney JR; Friedman GK; Zhang C; You Z; Zhao X; Ding Q; Kim K; Li H; Liu X; Markert JM; Nabors B; Gillespie GY; Zhao R; Han X
    J Neurooncol; 2019 Jan; 141(2):289-301. PubMed ID: 30460631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
    Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
    Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
    Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
    J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
    Wang Z; Bao Z; Yan W; You G; Wang Y; Li X; Zhang W
    J Exp Clin Cancer Res; 2013 Aug; 32(1):59. PubMed ID: 23988086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.
    Wang H; Wang X; Xu L; Zhang J
    World Neurosurg; 2023 Aug; 176():e610-e622. PubMed ID: 37271257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
    Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
    Kang X; Chen R; Zhang J; Li G; Dai PG; Chen C; Wang HJ
    Asian Pac J Cancer Prev; 2015; 16(8):3355-60. PubMed ID: 25921144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
    Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
    Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
    Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
    Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
    Lvu W; Fei X; Chen C; Zhang B
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
    Lv S; Teugels E; Sadones J; Quartier E; Huylebrouck M; DU Four S; LE Mercier M; DE Witte O; Salmon I; Michotte A; DE Grève J; Neyns B
    Anticancer Res; 2011 Dec; 31(12):4457-63. PubMed ID: 22199315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
    Nie QM; Lin YY; Yang X; Shen L; Guo LM; Que SL; Li XX; Ge JW; Wang GS; Xiong WH; Guo P; Qiu YM
    Mol Med Rep; 2015 Nov; 12(5):6695-701. PubMed ID: 26324126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.